[1]李文超,张东霞,魏 宏.子宫内膜癌组织错配修复蛋白表达及血液免疫炎症指标水平检测对术后生存的预测价值[J].现代检验医学杂志,2025,40(06):116-121.[doi:10.3969/j.issn.1671-7414.2025.06.021]
　LI Wenchao,ZHANG Dongxia,WEI Hong.Predictive Value of Endometrial Cancer Tissue Mismatch Repair Protein Expression and Detection of Blood Immune Inflammation Index Level for Postoperative Survival[J].Journal of Modern Laboratory Medicine,2025,40(06):116-121.[doi:10.3969/j.issn.1671-7414.2025.06.021]
点击复制

子宫内膜癌组织错配修复蛋白表达及血液免疫炎症指标水平检测对术后生存的预测价值()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年06期
页码:
116-121
栏目:
论著
出版日期:
2025-11-15

文章信息/Info

Title:
Predictive Value of Endometrial Cancer Tissue Mismatch Repair Protein Expression and Detection of Blood Immune Inflammation Index Level for Postoperative Survival
文章编号:
1671-7414（2025）06-116-06
作者:
李文超，张东霞，魏 宏
佳木斯市中心医院妇产科，黑龙江佳木斯 154002
Author(s):
LI Wenchao，ZHANG Dongxia，WEI Hong
Department of Obstetrics and Gynecology, Jiamusi Central Hospital, Heilongjiang Jiamusi 154002, China
关键词:
错配修复; 子宫内膜癌; 全身免疫炎症指数
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.06.021
文献标志码:
A
摘要:
目的探究子宫内膜癌（EC）组织错配修复（MMR）蛋白表达及血液免疫炎症指标水平检测对术后生存的预测价值。方法选取2017年1月～2020年1月佳木斯市中心医院收治的118例EC患者作为研究对象。通过免疫组织化学（IHC）分析EC组织中MMR蛋白状态，并根据染色结果将患者分为MMR蛋白缺乏组（dMMR组，n=40）和MMR丰富组（pMMR组，n=78）。计算术前全身免疫炎症指数（SII）；观察患者盆腔淋巴结状态；采用酶联免疫吸附试验（ELISA）检测患者血清肿瘤坏死因子-α（TNF-α），白细胞介素（IL）-1β，IL-6和C反应蛋白（CRP）水平。对两组的无病生存期（DFS）和总生存期（OS）及其影响因素进行分析。结果pMMR组与dMMR组患者年龄、FIGO分期、肿瘤组织病理学、盆腔淋巴结状态、SII比较，差异具有统计学意义（Z/t/χ2=3.202～11.151，均P＜0.05）。pMMR组和dMMR组患者的平均DFS分别为1477和756天，平均OS分别为1588和826天，差异具有统计学意义（LogRankχ2=24.804，30.411，均P＜0.001）。COX回归分析显示，SII是EC患者DFS的独立影响因素（Waldχ2=8.152，P＜0.05）；SII，盆腔淋巴结状态和MMR状态是EC患者OS的独立影响因素（Waldχ2=7.066，5.936，6.971，均P＜0.05）。MMR状态与SII联合预测EC患者DFS和OS的能力进一步提高，AUC分别为0.793，0.859，灵敏度分别为72.4%，75.0%，特异度分别为78.3%，80.0%。结论MMR状态和SII升高是EC患者术后预后不良的独立影响因素，二者组合有助于预测EC患者的DFS和OS。
Abstract:
Objective Predictive value of mismatch repair(MMR) protein expression in endometrial cancer(EC) tissues and blood immune-inflammatory marker levels on postoperative survival. Methods A total of 118 patients with EC who were treated at Jiamusi Central Hospital from January 2017 to January 2020 were selected as study subjects. The status of MMR proteins in endometrial cancer tissues was analyzed by immunohistochemistry, and based on the staining results, patients were divided into a MMR-deficient group (dMMR group, n=40) and a MMR-proficient group (pMMR group, n=78). The preoperative systemic immune-inflammation index (SII) was calculated. The pelvic lymph node status of the patients was observed. Enzyme-linked im-munosorbent assay (ELISA) was used to detect serum levels of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6 and C-reactive protein (CRP) in the patients. Disease-free survival (DFS) and overall survival (OS) as well as their influencing factors were analyzed between the two groups. Results Comparison of age, FIGO stage, tumor histopathology, pelvic lymph node status and SII between the pMMR group and dMMR groups in patients, and the differences were statistically significant (Z/t/χ2=3.202～11.151，all P＜0.05). The average DFS of patients in pMMR group and dMMR group was 1 477 days and 756 days, the average OS was 1 588 and 826 days respectively, and the differences between the two groups were statistically significant (Log Rank χ2=24.804, 30.411, all P<0.001). COX regression analysis showed that SII was an independent influencing factor of DFS in EC patients (Wald χ2=8.152, P<0.05). SII, pelvic lymph node status and MMR status were independent influencing factors of OS in EC patients (Wald χ2=7.066, 5.936, 6.971, all P<0.05). The ability of combining MMR status with SII to predict DFS and OS in EC patients was further improved, with AUC of 0.793 and 0.859, sensitivity of 72.4% and 75.0%, specificity of 78.3% and 80.0%, respectively. Conclusion MMR status and increased SII are independent influencing factors of poor postoperative prog-nosis of EC patients, and their combination is helpful to predict disease-free survival and overall survival of EC patients.

参考文献/References:

[1] 张清泉,王世军.子宫内膜癌手术质量控制[J].中国实用妇科与产科杂志, 2022, 38(1):25-27. ZHANG Q Q, WANG S J. Quality control of surgery for endometrial cancer[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2022, 38(1): 25-27.
[2] CONCIN N, MATIAS-GUIU X, VERGOTE I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma[J]. International Journal of Gynecological Cancer, 2021, 31(1): 12-39.
[3] BOENNELYCKE M, PETERS E E M, L?ON-CAS-TILLO A, et al. Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort[J]. Virchows Archiv, 2021, 479(3): 507-514.
[4] LOUKOVAARA M, PASANEN A, BUTZOW R. Mis-match repair deficiency as a predictive and prognostic biomarker in molecularly classified endometrial carci-noma [J]. Cancers, 2021, 13(13): 3124.
[5] RAFFONE A, CATENA U, TRAVAGLINO A, et al. Mismatch repair-deficiency specifically predicts re-currence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment:a multi-center study[J]. Gynecologic Oncology, 2021, 161(3): 795-801.
[6] DEDEURWAERDERE F, CLAES K B, VAN DORPE J, et al. Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer[J]. Scientific Re-ports, 2021, 11(1): 12880.
[7] 伍雯莹,黄娅芬,梅巧.子宫内膜癌组织中IGF2BP1 mRNA, PEG10 mRNA表达及与增殖基因表达的相关性和预后研究[J].现代检验医学杂志,2024,39(4):16-22. WU W Y, HUANG Y F, MEI Q. Expression of IG-F2BP1 mRNA and PEG10 mRNA in endometrial cancer tissues and their correlation with proliferation gene expression and prognosis[J]. Journal of Modern Laboratory Medicine, 2024, 39(4): 16-22.
[8] INOUE F, SONE K, TOYOHARA Y, et al. Targeting epigenetic regulators for endometrial cancer therapy: its molecular biology and potential clinical applications[J]. International Journal of Molecular Sciences, 2021, 22(5): 2305.
[9] 陆瑞,郭红霞,吴苗苗,等.KIF18B通过激活Wnt/βcat-enin信号通路促进子宫内膜癌细胞增殖和转移的实验研究[J].现代检验医学杂志,2023,38(5):58-62, 69. LU R, GUO H X, WU M M, et al. Experimental study on KIF18B promoting proliferation and metastasis of endometrial cancer cells by activating the Wnt/β-cat-enin signaling pathway [J]. Journal of Modern Labora-tory Medicine, 2023, 38(5): 58-62, 69.
[10] ILANGO S, PAITAL B, JAYACHANDRAN P, et al.Epigenetic alterations in cancer[J]. Frontiers in Biosci-ence, 2020, 25(6): 1058-1109.
[11] RIEDINGER C J, ESNAKULA A, HAIGHT P J, et al. Characterization of mismatch-repair (MMR)/micro-satellite instability (MSI)‐discordant endometrial can-cers[J]. Cancer, 2023, 130(3): 385-399.
[12] HUANG M, HUNTER T, FEIN L A, et al. Lost oppor-tunities for mismatch repair (MMR) screening among minority women with endometrial cancer[J]. Scientific Reports, 2021, 11(1): 11712.
[13] TIMMERMAN S, VAN ROMPUY A S, VAN GORP T, et al. Analysis of 108 patients with endometrial carci-noma using the PROMISE classification and additional genetic analyses for MMR-D[J]. Gynecologic Oncolo-gy, 2020, 157(1): 245-251.
[14] 张亚军,刘裴丽,江月,等.子宫内膜癌组织中dMMR蛋白和miRNA Let-7表达水平及临床价值的研究[J].现代检验医学杂志,2024,39(3):48-52, 108. ZHANG Y J, LIU P L, JIANG Y, et al. Expression level and clinical value of dMMR proteins and miRNA Let-7 in endometrial carcinoma tissue[J]. Journal of Modern Laboratory Medicine, 2024, 39(3): 48-52, 108.
[15] GUO Y, LIU Y, ZHANG W, et al. The clinicopatho-logical characteristics, prognosis and immune micro-environment mapping in MSI-H/MMR-D endometrial carcinomas[J]. Discover Oncology, 2022, 13(1): 12.
[16] RIEDINGER C J, BROWN M, HAIGHT P J, et al. Epigenetic MMR defect identifies a risk group not ac-counted for through traditional risk stratification algo-rithms in endometrial cancer[J]. Frontiers in Oncology, 2023, 13: 1147657.
[17] LEI H F, XU S X, MAO X D, et al. Systemic im-mune-inflammatory index as a predictor of lymph node metastasis in endometrial cancer[J]. Journal of Inflam-mation Research, 2021, 14: 7131-7142.
[18] CROSBIE E J, KITSON S J, MCALPINE J N, et al. Endometrial cancer[J]. Lancet, 2022, 399(10333):1412-1428.
[19] HUANG Y H, CHEN Y, ZHU Y, et al. Postoperative systemic immune-inflammation index (SII): a superior prognostic factor of endometrial cancer[J]. Frontiers in Surgery, 2021, 8: 704235.
[20] LOI S, MICHIELS S, ADAMS S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibi-tion[J]. Annals of Oncology, 2021, 32(10): 1236-1244.
[21] GUNNARSSON U, STRIGARD K, EDIN S, et al. Association between local immune cell infiltration, mismatch repair status and systemic inflammatory re-sponse in colorectal cancer[J]. Journal of Translational Medicine, 2020, 18(1): 178.
[22] LI J J, ZHANG Y W, XU Q, et al. Systemic inflamma-tory markers of resectable colorectal cancer patients with different mismatch repair gene status[J]. Cancer Management and Research, 2021, 13: 2925-2935.

相似文献/References:

[1]李 玲,罗雅文,何 霞,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
　LI Ling,LUO Ya-wen,HE Xia,et al.Diagnostic Value of Combined Detection of Body Mass Index and Serum HE4,CA125 in Patients with Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(06):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
[2]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
　LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(06):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
[3]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
　WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[4]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
　LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(06):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[5]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
　CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[6]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
　CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
[7]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
　LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(06):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[8]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
　PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(06):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[9]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
　LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(06):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
[10]陆 瑞,郭红霞,吴苗苗,等.KIF18B 通过激活Wnt/β catenin 信号通路促进子宫内膜癌细胞增殖和转移的实验研究[J].现代检验医学杂志,2023,38(05):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
　LU Rui,GUO Hongxia,WU Miaomiao,et al.Experimental Study of KIF18B Promoting Endometrial Cancer Cell Proliferation and Metastasis by Activating Wnt/β-catenin Signaling Pathway[J].Journal of Modern Laboratory Medicine,2023,38(06):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]

备注/Memo

备注/Memo:
基金项目：黑龙江省卫生健康委科研项目（20210505010398）。
作者简介：李文超（1984-），女，硕士，副主任医师，研究方向：妇科肿瘤，E-mail：bixwr27@163.com。
更新日期/Last Update: 2025-11-15